DCGI asks Serum Institute to revise protocol for phase 2, 3 trials of Oxford COVID-19 vaccine
A CDSCO expert panel has sought clarifications from Serum Institute of India (SII) over its application to the DCGI seeking permission for conducting phase 2 and 3 human clinical trials of the Oxford vaccine candidate for COVID-19, official sources said on Wednesday. On Wednesday evening, SII submitted a revised protocol for conducting the trials to the DCGI.
You Might Like
💡 newsR Knowledge: Other News Mentions
Bharat Biotech's Covaxin 77.8 per cent effective in protecting against COVID-19| Oneindia News
Credit: Oneindia Duration: 02:03Published
Bharat biotech submits phase 3 trial data, expert panel meet today| Covaxin | Oneindia News
Credit: Oneindia Duration: 02:02Published
Gautam Gambhir Foundation guilty of hoarding FabiFlu Covid vaccine: DGCA| Delhi HC | Oneindia News
Credit: Oneindia Duration: 01:45Published
Pfizer and Moderna vaccines may arrive in India soon| DCGI paves the way | Oneindia News
Credit: Oneindia Duration: 02:05Published
Oxford vaccine scientists honoured for 'high-stakes endeavour'
Credit: PA - Press Association STUDIO Duration: 02:50Published
Age threshold for alternative to AstraZeneca jab raised
Credit: PA - Press Association STUDIO Duration: 00:38Published
Under-40s in UK to get alternative Covid jab to AstraZeneca
Credit: ODN Duration: 01:00Published
Vaccine production is truly international collaboration in India: EAM
Credit: ANI Duration: 01:57Published
Watch: Congress responds to Adar Poonawalla’s ‘being threatened’ charge
Credit: HT Digital Content Duration: 02:05Published
Serum Institute's COVID-19 vaccine 'Covovax' likely to launch by SeptemberThe new vaccine shall be launched under the brand name of Covovax, which SII is manufacturing in partnership with US pharmaceutical firm Novovax.
SII, Bharat Biotech seek hike in government price for Covid vaccinesSerum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield..
COVID-19: Serum Institute's Novavax vaccine shows 90% overall efficacyNovavax in collaboration with Indian drug manufacturer Serum Institute of India is manufacturing these vaccines for India and low-income countries.
Covid-19: Novavax set for India launch with Serum Institute of India as manufacturing partnerThe uncertain path to authorisation in the US for Novavax despite passing the efficacy test with an impressive score of 90.4% might see India emerge as a major..
Novavax vaccine over 90% effective in U.S. trial
Credit: Reuters - Politics Duration: 01:41Published
Nicola Sturgeon delays Scotland unlocking
Credit: ODN Duration: 01:27Published
SC approves scheme proposed to calculate the marks for students of Class 12| CBSE| Oneindia News
Credit: Oneindia Duration: 02:06Published
'Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trials'Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the..
Related videos from verified sources
Related news from verified sources